Table 3. Univariate and multivariate analyses of the RFS.
| Characteristics | RFS | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR (95% CI) | p-value* | HR (95% CI) | p-value† | |
| Age (≥ 50 vs. < 50 yr) | 0.880 (0.390–1.990) | 0.761 | - | - |
| Hypertension (yes vs. no) | 0.790 (0.240–2.650) | 0.703 | - | - |
| Hyperlipidemia (yes vs. no) | 0.440 (0.060–3.310) | 0.429 | - | - |
| BMI (≥ 23 vs. < 23 kg/m2) | 0.500 (0.220–1.120) | 0.090 | 0.477 (0.199–1.145) | 0.098 |
| Tumor location (left vs. right) | 1.240 (0.560–2.760) | 0.598 | - | - |
| BCS (no vs. yes) | 2.230 (1.000–4.960) | 0.050 | 1.075 (0.433–2.665) | 0.876 |
| SLNB (no vs. yes) | 1.920 (0.760–4.840) | 0.168 | 1.569 (0.589–4.179) | 0.367 |
| Pathologic subtype (others vs. IDC) | 1.160 (0.270–4.980) | 0.844 | - | - |
| T stage (≥ T2 vs. T1) | 4.430 (1.510–13.010) | 0.007 | 3.649 (1.216–10.947) | 0.021 |
| N stage (≥ N1 vs. N0) | 1.440 (0.530–3.890) | 0.469 | - | - |
| Estrogen receptor (positive vs. negative) | 0.600 (0.260–1.370) | 0.224 | - | - |
| Progesterone receptor (positive vs. negative) | 0.700 (0.310–1.600) | 0.397 | - | - |
| HER-2 (positive vs. negative) | 1.010 (0.440–2.310) | 0.990 | - | - |
| Vascular invasion (present vs. absent) | 4.230 (0.980–18.250) | 0.053 | 5.088 (1.037–24.954) | 0.045 |
| Lymphatic invasion (present vs. absent) | 0.620 (0.150–2.640) | 0.518 | - | - |
| p53 (positive vs. negative) | 1.030 (0.460–2.320) | 0.949 | - | - |
| Ki67 (positive vs. negative) | 2.080 (0.780–5.570) | 0.146 | 1.742 (0.623–4.875) | 0.290 |
| Radiotherapy (yes vs. no) | 1.090 (0.370–3.200) | 0.872 | - | - |
| Hormone therapy (yes vs. no) | 0.640 (0.280–1.510) | 0.309 | - | - |
| Target therapy (yes vs. no) | 1.100 (0.480–2.530) | 0.819 | - | - |
| Hyperglycemia (yes vs. no) | 2.970 (1.220–7.220) | 0.016 | 3.504 (1.390–8.836) | 0.008 |
RFS = relapse-free survival; HR = hazard ratio; CI = confidence interval; BMI = body mass index; BCS = breast conserving surgery; SLNB = sentinel lymph node biopsy; IDC = invasive ductal carcinoma; HER-2 = human epidermal growth factor receptor 2.
*Kaplan-Meier survival estimates compared by log-rank test; †Cox proportional hazards model.